Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
Dr. Reddy’s Laboratories Limited (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada.
This move is significant as it positions Dr. Reddy’s among the first companies to introduce this generic product in the Canadian market, which is a notable expansion for the company after receiving approval from Health Canada.
Dr. Reddy’s has launched its generic Semaglutide Injection, indicated for the treatment of type 2 diabetes, shortly after receiving market authorization on April 28, 2026. This launch underscores the company’s commitment to enhancing patient access to affordable medications in Canada, a market where it aims to establish a strong foothold.
Despite the positive news for Dr. Reddy’s, the broader market faced challenges, with major indices like the Nasdaq down 1.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
